Arcion Therapeutics

9 articles about Arcion Therapeutics

• 

  CEO Kerrie Brady Organizes OcuTerra for Success Against Diabetic Retinopathy

  2/2/2022

  OcuTerra Therapeutics aims to exchange watching and waiting for active treatment with a non-invasive eyedrop that reaches the retina and, therefore, allows treatment to occur much earlier in the disease.

• Arcion Therapeutics Receives Notice of Allowance for US Patent for Novel Topical Lidocaine Formulation for Pain

  1/4/2012

• Arcion Therapeutics to Present ARC-4558 Phase 2b Data for the Treatment of Pain Associated With Painful Diabetic Neuropathy at Upcoming Medical Meetings

  6/14/2011

• Arcion Therapeutics Receives FDA Fast Track Designation for ARC-4558 for the Treatment of Pain Associated with Painful Diabetic Neuropathy

  9/14/2010

• Arcion Therapeutics' Topical Gel Candidate, ARC-4558, Demonstrates Significant Pain Reduction in Phase 2b Trial for Painful Diabetic Neuropathy (PDN)

  7/20/2010

• Anesiva, Inc. Stockholders Approved Merger With Arcion Therapeutics; Merger Remains Contingent on Other Closing Conditions

  12/8/2009

• Anesiva, Inc. and Arcion Therapeutics Announce Merger Agreement; Creates New Company Focused on Targeted Pain Therapeutics

  8/5/2009

• Arcion Therapeutics' Topical Pain Candidate, ARC-4558, Significantly Reduces Pain Caused by Diabetic Neuropathy

  5/7/2009

• Arcion Therapeutics Raises $8.8 Million ''A'' Round

  1/9/2008